306 related articles for article (PubMed ID: 21261567)
21. Immunotherapy for Alzheimer's disease.
Solomon B; Frenkel D
Neuropharmacology; 2010; 59(4-5):303-9. PubMed ID: 20388523
[TBL] [Abstract][Full Text] [Related]
22. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
Kuzuhara S
Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
[TBL] [Abstract][Full Text] [Related]
23. Current progress in beta-amyloid immunotherapy.
Schenk D; Hagen M; Seubert P
Curr Opin Immunol; 2004 Oct; 16(5):599-606. PubMed ID: 15342006
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy against amyloid pathology in Alzheimer's disease.
Galimberti D; Ghezzi L; Scarpini E
J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047
[TBL] [Abstract][Full Text] [Related]
25. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
[TBL] [Abstract][Full Text] [Related]
26. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
27. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.
Davtyan H; Zagorski K; Rajapaksha H; Hovakimyan A; Davtyan A; Petrushina I; Kazarian K; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A
Sci Rep; 2016 Jul; 6():28912. PubMed ID: 27363809
[TBL] [Abstract][Full Text] [Related]
29. Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.
Plotkin SS; Cashman NR
Neurobiol Dis; 2020 Oct; 144():105010. PubMed ID: 32682954
[TBL] [Abstract][Full Text] [Related]
30. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
Boche D; Denham N; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
[TBL] [Abstract][Full Text] [Related]
31. [Aβ immunotherapy for Alzheimer's disease].
Sakai K; Yamada M
Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
[TBL] [Abstract][Full Text] [Related]
32. Solanezumab for Alzheimer's disease.
Samadi H; Sultzer D
Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of vaccines for Alzheimer's disease.
Shah S; Federoff HJ
Immunotherapy; 2011 Feb; 3(2):287-98. PubMed ID: 21322764
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for Alzheimer's disease.
Gelinas DS; DaSilva K; Fenili D; St George-Hyslop P; McLaurin J
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14657-62. PubMed ID: 15297619
[TBL] [Abstract][Full Text] [Related]
35. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
36. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
37. [One hundred years of Alzheimer's disease: immunotherapy a hope?].
Behrens P MI; Vergara E F
Rev Med Chil; 2007 Jan; 135(1):103-10. PubMed ID: 17369991
[TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease: a general introduction and pathomechanism.
Finder VH
J Alzheimers Dis; 2010; 22 Suppl 3():5-19. PubMed ID: 20858960
[TBL] [Abstract][Full Text] [Related]
39. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
Herline K; Drummond E; Wisniewski T
Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
